Diabetes Mellitus, Type 2
Conditions
Brief summary
To evaluate the efficiency of Lantus plus combined oral hypoglycaemic agents in terms of respondents percentage. The respondent is defined as the person achieving a value in the final determination of HbA1c \< 7% as its absolute value and/or a decreasing in the final value of HbA1c of more than 12% compared with the initial value (final HbA1c vs. initial HbA1c). Describe the glycemia levels and body weight change in the two response groups, (respondents and non-respondents). Describe the adverse events Evaluate the safety of using the medication according to the incidence and relevance of the hypoglycemia events, (symptomatic, diurnal, nocturnal, severe). Estimate the intra-patient variability of the fasting glycemia
Interventions
DRUGInsulin glargine
Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
Sponsors
Sanofi
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with type 2 diabetes mellitus receiving antidiabetic treatment (1 or 2 oral agents) during more than 6 months, who need a prolonged action basal insulin to control hyperglycemia * Glycosylated hemoglobin \> 8,0% and \< 10 % * Body mass index (BMI) \< 40 kg/m2 * Voluntary acceptation of the treatment and capability to self inject the insulin glargine * Capability and desire to carry out self-determination of glycemia levels using glucometers
Exclusion criteria
* Renal function disorder, revealed by a serum creatinine \> 177 µmol/l (\> 2,0 mg/dl) in Visit 1 or currently undergoing kidney dialysis * Acute metabolic acidosis (\> 1 episode during the last year) or chronic, including diabetic ketoacidosis * Clinical evidence of an active liver disease or serum ALT/AST \>2.5 times the upper normality limit * A history of unnoticed hypoglycemia * Surgical treatment for diabetic retinopathy, (laser photocoagulation or a vitrectomy), during the three months prior to joining the trial, or patient that has needed treatment within three months of entering the trial * Pregnancy or breast feeding * Not using an adequate birth control method, (only for potentially fertile females) : for example, the use of systemic hormones, (pills or birth control implants), intrauterine devices or a barrier method, (diaphragm with intra-vaginal spermicides, male or female preservative) * Known hypersensitivity to insulin glargine or any of its excipients * Malignant process, except for basal carcinoma cells during the last five years * More than two weeks of continuous treatment with systemic glucocorticoids in the last 6 months * Concomitant treatment with non-cardio selective beta blockers * Known supra-renal failure * Known hemoglobinopathy or anemia, uncontrolled or unstable * A psychiatric disturbance which prevents the patient from understanding the nature, objective and possible consequences of the trial * A history of drug or alcohol abuse in the last two years or any current addiction * Current use of insulin glargine * Any clinically relevant, cardiovascular, hepatic, neurological, endocrinal or systemic major disease, or any other type, which may hinder the development of the protocol or the interpretation of the results of the trial * Known existence of GAD (glutamic acid decarboxylase) antibodies * Type 1 diabetes mellitus, according to its definition by the WHO * The use of a drug being researched other than insulin during six months prior to joining the trial or the use of an insulin under study during four weeks before entering the trial * A history of severe hypoglycemia with repeated blackouts, (more than 1), during the last year The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the initial vs. final values of HbA1c | 9 months |
| Number of severe hypoglycemia | 9 months |
Secondary
| Measure | Time frame |
|---|---|
| - Change in the fasting glucose values with each visit | 9 months |
| - Incidences of symptomatic and asymptomatic nocturnal hypoglycemia - Evaluations of safety with regards to the use of insulin glargine, recording the adverse events, excluding hypoglycemia - Abnormal laboratory results | 9 months |
| - Change in body weight initial visit vs. final visit | 9 months |
Countries
Mexico
Outcome results
None listed